Quartix Technologies (LON:QTX) May Have Issues Allocating Its Capital

If you're looking at a mature business that's past the growth phase, what are some of the underlying trends that pop up? Typically, we'll see the trend of both return on capital employed (ROCE) declining and this usually coincides with a decreasing amount of capital employed. Trends like this ultimately mean the business is reducing its investments and also earning less on what it has invested. Having said that, after a brief look, Quartix Technologies (LON:QTX) we aren't filled with optimism, but let's investigate further.

Advertisement

Return On Capital Employed (ROCE): What Is It?

If you haven't worked with ROCE before, it measures the 'return' (pre-tax profit) a company generates from capital employed in its business. The formula for this calculation on Quartix Technologies is:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

0.072 = UK£1.3m ÷ (UK£29m - UK£11m) (Based on the trailing twelve months to December 2023).

Thus, Quartix Technologies has an ROCE of 7.2%. In absolute terms, that's a low return but it's around the Software industry average of 8.4%.

See our latest analysis for Quartix Technologies

roce
AIM:QTX Return on Capital Employed June 1st 2024

In the above chart we have measured Quartix Technologies' prior ROCE against its prior performance, but the future is arguably more important. If you're interested, you can view the analysts predictions in our free analyst report for Quartix Technologies .

The Trend Of ROCE

There is reason to be cautious about Quartix Technologies, given the returns are trending downwards. About five years ago, returns on capital were 45%, however they're now substantially lower than that as we saw above. And on the capital employed front, the business is utilizing roughly the same amount of capital as it was back then. Since returns are falling and the business has the same amount of assets employed, this can suggest it's a mature business that hasn't had much growth in the last five years. If these trends continue, we wouldn't expect Quartix Technologies to turn into a multi-bagger.

The Key Takeaway

In summary, it's unfortunate that Quartix Technologies is generating lower returns from the same amount of capital. It should come as no surprise then that the stock has fallen 28% over the last five years, so it looks like investors are recognizing these changes. That being the case, unless the underlying trends revert to a more positive trajectory, we'd consider looking elsewhere.

If you want to continue researching Quartix Technologies, you might be interested to know about the 1 warning sign that our analysis has discovered.

While Quartix Technologies may not currently earn the highest returns, we've compiled a list of companies that currently earn more than 25% return on equity. Check out this free list here.

Valuation is complex, but we're here to simplify it.

Discover if Quartix Technologies might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About AIM:QTX

Quartix Technologies

Designs, develops, markets, and delivers vehicle telematics services in the United Kingdom, France, the United States, and other European Territories.

Flawless balance sheet with reasonable growth potential.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
47 users have followed this narrative
2 users have commented on this narrative
7 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.4% undervalued
69 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
23 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
24 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative

Updated Narratives

WI
WisetoWealth
PYPL logo
WisetoWealth on PayPal Holdings ·

The Underrated Transformation of a Digital Payments Giant

Fair Value:US$90.3137.8% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BL
Blagget
TERA logo
Blagget on Terra Balcanica Resources ·

The C$4M Explorer Positioned to Become Europe's First Antimony Mine

Fair Value:CA$0.487.5% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DA
CHTR logo
david_6nroa on Charter Communications ·

Charter is undervalued - Here's why.

Fair Value:US$87.0741.6% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
81 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28026.1% undervalued
186 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
72 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0